Severe Mpox Infections in People With Uncontrolled Human Immunodeficiency Virus.

Autor:	Govind A; Division of Infectious Diseases and Geographic Medicine, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.; Parkland Health, Dallas, Texas, USA., Lazarte SM; Division of Infectious Diseases and Geographic Medicine, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.; Parkland Health, Dallas, Texas, USA., Kitchell E; Division of Infectious Diseases and Geographic Medicine, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.; Parkland Health, Dallas, Texas, USA., Chow JY; Division of Infectious Diseases and Geographic Medicine, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.; Parkland Health, Dallas, Texas, USA., Estelle CD; Division of Infectious Diseases and Geographic Medicine, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.; Parkland Health, Dallas, Texas, USA., Fixsen E; Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas, USA., Helm C; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA., Jain MK; Division of Infectious Diseases and Geographic Medicine, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.; Parkland Health, Dallas, Texas, USA., Mehta R; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA., Perl TM; Division of Infectious Diseases and Geographic Medicine, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.; Parkland Health, Dallas, Texas, USA., Sutaria JM; Parkland Health, Dallas, Texas, USA.; Division of Hospital Medicine, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA., Thomas C; Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA., Dominguez AR; Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA., Utay NS; Division of Infectious Diseases and Geographic Medicine, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.; Parkland Health, Dallas, Texas, USA.
Jazyk:	angličtina
Zdroj:	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2023 May 24; Vol. 76 (10), pp. 1843-1846.
DOI:	10.1093/cid/ciad052
Abstrakt:	In the current mpox outbreak, infections are usually self-limited. We describe 3 patients with uncontrolled HIV and mpox infections lasting months, causing debilitating lesions, complications, and death, despite initiating anti-mpox and antiretroviral therapy. Delayed treatment of mpox with antiviral agents may contribute to poor outcomes in severely immunocompromised patients. Competing Interests: Potential conflicts of interest. C. D. E. reports unpaid roles on the Board of Directors for Dallas County Medical Society and an unpaid role as an executive board member of the CV Roman Medical Society (DFW Chapter of the National Medical Association); receipt of drugs given to their institution for use in the patient from Dallas County Health and Human Services (from the CDC) for tecovirimat and VIGIV and from the Food and Drug Administration (FDA) for brincidofovir. A. G. reports receipt of drugs given to their institution for use in the patient from Dallas County Health and Human Services (from the CDC) for tecovirimat and VIGIV. J. Y. C. reports grants or contracts from Gilead Sciences for Investigator Sponsored Research unrelated to the topic of this manuscript and receipt of drugs given to their institution for use in the patient from Dallas County Health and Human Services (from the CDC) for tecovirimat and VIGIV. S. M. L. reports grants or contracts from Gilead Sciences as Site Principal Investigator for a Purpose 2 clinical trial regarding lenacapavir as pre-exposure prophylaxis (PrEP; payment to institution) and receipt of drugs given to their institution for use in the patient from Dallas County Health and Human Services (from the CDC) for tecovirimat and VIGIV. M. K. J. reports grants or contracts to the institution from Gilead Sciences, GSK/ViiV, Merck, and Janssen and receipt of drugs given to their institution for use in the patient from Dallas County Health and Human Services (from the CDC) for tecovirimat and VIGIV and from FDA for brincidofovir. E. K. reports receipt of drugs given to their institution for use in the patient from Dallas County Health and Human Services (from the CDC) for tecovirimat and VIGIV and from FDA for brincidofovir. T. M. P. reports receipt of drugs given to their institution for use in the patient from Dallas County Health and Human Services (from the CDC) for tecovirimat and VIGIV. N. S. U. reports receipt of drugs given to their institution for use in the patient from Dallas County Health and Human Services (from the CDC) for tecovirimat and VIGIV and from FDA for brincidofovir. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. (© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu